All In Biotech

Free tool

FAERS Monitor: Invanz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021337 or its brand name (Invanz, Ertapenem Sodium). Reports on generic versions are filed under their own applications.

Reports

7,465

Serious

6,366

85% of reports

Hospitalization

3,473

Death reported

639

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,161
  • macular degeneration808
  • off label use539
  • pyrexia467
  • confusional state441
  • product use in unapproved indication434
  • nausea397
  • pain345
  • weight decreased274
  • malaise271
  • anaemia268
  • hallucination266
  • abdominal pain244
  • headache239
  • seizure232

Reports by year received

View as table
YearReports
2004115
200560
200693
2007117
2008125
2009103
2010117
2011138
2012246
2013287
2014279
2015347
2016318
2017284
2018425
2019429
2020483
2021768
2022633
2023585
2024589
2025538
2026386

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,694 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
macular degenerationSignal808204.3191.0152,348
hallucinationSignal26610.08.92,139
confusional stateSignal4417.77.02,580
seizureSignal2325.75.0890
product use in unapproved indicationSignal4344.94.51,374
anaemiaSignal2684.03.5595
pyrexiaSignal4673.83.5978
abdominal painSignal2443.02.6317
weight decreasedSignal2742.82.5311
drug ineffectiveSignal1,1612.52.41,095
malaise2711.71.587
off label use5391.71.6174
pain3451.61.476
nausea3971.41.349
headache2391.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.